The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 20, 2023

Filed:

Feb. 28, 2018
Applicants:

Xiamen University, Xiamen, CN;

Yang Sheng Tang Company, Ltd., Haikou, CN;

Inventors:

Chenghao Huang, Xiamen, CN;

Yong Luo, Xiamen, CN;

Quan Yuan, Xiamen, CN;

Jun Zhang, Xiamen, CN;

Ningshao Xia, Xiamen, CN;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 7/00 (2006.01); A61P 35/00 (2006.01); A61K 35/763 (2015.01); C07K 14/005 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
C12N 7/00 (2013.01); A61K 35/763 (2013.01); A61P 35/00 (2018.01); C07K 14/005 (2013.01); C12N 15/86 (2013.01); C12N 2710/16621 (2013.01); C12N 2710/16622 (2013.01); C12N 2710/16643 (2013.01); C12N 2710/16651 (2013.01);
Abstract

The invention relates to the field of virology and tumor therapy. In particular, the present invention provides a recombinant herpes simplex virus (HSV) capable of specifically replicating at a high level in a tumor cell and effectively killing the tumor cell, but replicating at low levels in normal cells, thereby the recombinant herpes simplex virus of the present invention not only has high lethality against tumor cells, but also has significantly decreased side effects (especially neurotoxicity). Further, the present invention relates to a viral vector constructed based on the recombinant herpes simplex virus, a pharmaceutical composition comprising the recombinant herpes simplex virus or the viral vector, and the use of the recombinant herpes simplex virus or the viral vector. The recombinant herpes simplex virus of the present invention can be used to infect and kill tumor cells, and can be used for gene drug delivery into tumor cells for gene therapy.


Find Patent Forward Citations

Loading…